• Product NameBosutinib
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityBosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.
• Target NameBcr-Abl inhibitor; MAPK inhibitor; Src inhibitor
• CAS No. 380843-75-4
• Calculated MW 530.45
• Formulation C26H29Cl2N5O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
  Pathways:Angiogenesis; MAPK; Cytoskeletal Signaling
  Receptor:Abl; MAPK; c-Src
  Boling pt:649.7C
  Melting pt:116-120C
  Solubility:Ethanol: 2 mg/mL (3.77 mM); DMSO: 100 mg/mL (188.51 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Remsing Rix LL, et al. Leukemia. 2009 Mar;23(3):477-85. .

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting